Abstract
Abstract
Background
Trichomonas vaginalis is the causative agent of trichomoniasis, which is one of the most common sexually transmitted diseases worldwide. Trichomoniasis has a high incidence and prevalence and is associated with serious complications such as HIV transmission and acquisition, pelvic inflammatory disease and preterm birth. Although trichomoniasis is treated with oral metronidazole (MTZ), the number of strains resistant to this drug is increasing (2.5–9.6%), leading to treatment failure. Therefore, there is an urgent need to find alternative drugs to combat this disease.
Methods
Herein, we report the in vitro and in silico analysis of 12 furanyl N-acylhydrazone derivatives (PFUR 4, a-k) against Trichomonas vaginalis. Trichomonas vaginalis ATCC 30236 isolate was treated with seven concentrations of these compounds to determine the minimum inhibitory concentration (MIC) and 50% inhibitory concentration (IC50). In addition, compounds that displayed anti-T. vaginalis activity were analyzed using thiobarbituric acid reactive substances (TBARS) assay and molecular docking. Cytotoxicity analysis was also performed in CHO-K1 cells.
Results
The compounds PFUR 4a and 4b, at 6.25 µM, induced complete parasite death after 24 h of exposure with IC50 of 1.69 µM and 1.98 µM, respectively. The results showed that lipid peroxidation is not involved in parasite death. Molecular docking studies predicted strong interactions of PFUR 4a and 4b with T. vaginalis enzymes, purine nucleoside phosphorylase, and lactate dehydrogenase, while only PFUR 4b interacted in silico with thioredoxin reductase and methionine gamma-lyase. PFUR 4a and 4b led to a growth inhibition (< 20%) in CHO-K1 cells that was comparable to the drug of choice, with a promising selectivity index (> 7.4).
Conclusions
Our results showed that PFUR 4a and 4b are promising molecules that can be used for the development of new trichomonacidal agents for T. vaginalis.
Funder
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference50 articles.
1. WHO. Global incidence and prevalence of selected curable sexually transmitted infections-2008. Geneva: World Health Organization; 2012. https://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/. Accessed 31 Aug 2019.
2. Grama DF, da Casarotti LS, de Morato MGVA, Silva LS, Mendonça DF, Limongi JE, et al. Prevalence of Trichomonas vaginalis and risk factors in women treated at public health units in Brazil: a transversal study. Trans R Soc Trop Med Hyg. 2013;107:584–91.
3. Rocha DAP, Filho RAAB, Mariño JM, dos Santos CMB. “Hidden” sexually transmitted infections among women in primary care health services, Amazonas, Brazil. Int J STD AIDS. 2014;25:878–86.
4. Bruni MP, Lopes S, Stauffert D, Caetano C, Filho C, Siqueira L, et al. Trichomonas vaginalis infection among women attending frequency, risk factors and clinical signs. DST-J bras Doenças Sex Transm. 2015;27:86–91.
5. Ambrozio CL, Nagel AS, Jesk S, Bragança GCM, Borsuk S, Villela MM. Trichomonas vaginalis prevalence and risk factors for women in southern Brazil. Rev Inst Med Trop Sao Paulo. 2016;58:1–5.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献